Also It's Ramadan Feast!
#eidalfitr #ramadan #digitalart #jco

Me, My Sister, Lexon, Carolu and Lexon Jr. are celebrating JCO's Philippines 14th Anniversary #digitalart #starpowers #thelentituds #jco #originalcharacter

New #ASCO #JCO Cancer Stories: "A Chance to Heal with Cold Hard Steel" with host @mikkaelsekeres.bsky.social. Dr. Taylor Goodstein shares a powerful perspective on surgery, grief, and finding courage within our own fallibility.

Tune in: https://bit.ly/4rG0nQL

In the latest #JCO Cancer Stories with host Dr. @mikkaelsekeres.bsky.social

Dr. Henry Bair shares a moving account of how vision care can honor end-of-life goals—helping a patient with failing sight write to his children.

Listen here: https://bit.ly/3ZxVYD9
#ArtOfOncology

Four manuscripts of out 51 published last year on the topics of bladder, pancreatic, colorectal and skin cancer were chosen by the Alliance for Clinical Trials in Oncology Publications Committee as the most significant of the year. https://bit.ly/Top4-2025 NEJM.org #jnci #jco #NCI #clinicaltrials

Just published in #JCO, @jmikhaelmd.bsky.social & @lisakhicks.bsky.social introduce a new @ascocancer.bsky.social living guideline w/ updated recommendations for multiple myeloma therapy in differing variants and pt populations.

Learn more: brnw.ch/21wYSoe

Listen to the latest #ASCO #JCO Cancer Stories: The Art of Oncology with host @mikkaelsekeres.bsky.social.

In this episode "Smell” with Dr. Cusick shares a connection to a cancer patient manifested as a scent.

🎧: ascopubs.org/do/smell-sce...

A man stands at a podium in front of a slide, the top of which reads "Conclusions: there are many ways to lose your shirt"

Wisdom from #JCO assoc editor Bob Maki at #CTOS25:

“There are many ways to lose your shirt. Las Vegas, Crypto, and [bad] statistical design.”

#JCO keep on delivering !

As someone who rather likes the writing of Joyce Carol Oates, I didn't think she'd do her best work in 2025. #JCO #Elon

Long after #ElonMusk & his mediocre status symbols for sociopaths #Te⚡️⚡️las & rapid unscheduled exploding #SpaceXplodes rockets are confined to history’s #MuseumOfUselessMediocrities, books written by people who love & appreciate people, art, books, & LIFE, will endure.
#JCO

She's spot on! This is why I express empathy, contempt, and sadness for 47's children and grandchildren. I thank God every day for the values I was raised with- Humility over arrogance. #JCO Always speak truth to power.

Don't be fooled by her age. Joyce Carol Oates knows how to throw a punch. #JCO

First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation PURPOSEZelenectide pevedotin (BT8009) is a Bicycle Drug Conjugate comprising a highly selective Nectin-4–targeting Bicycle peptide, linked to monomethyl auristatin E. We report monotherapy…

How did this play out in real life?

In this #JCO study, expected very short half-life (~1 hr) of the full compound, and MMAE half life between 37-50 hours with no accumulation between cycles.

- 33% neuropathy vs 67% w EV/pembro
- 22% skin tox vs 52% rash w EV

ascopubs.org/doi/10.1200/...

First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation PURPOSEZelenectide pevedotin (BT8009) is a Bicycle Drug Conjugate comprising a highly selective Nectin-4–targeting Bicycle peptide, linked to monomethyl auristatin E. We report monotherapy…

How did this play out in real life?

In this #JCO study, expected very short half-life (~1 hr) of the full compound, and MMAE half life between 37-50 hours with no accumulation between cycles.

- 33% neuropathy vs 67% w EV/pembro
- 22% skin tox vs 52% rash w EV

ascopubs.org/doi/10.1200/...

Listen to the latest @ascocancer.bsky.social #JCO Cancer Stories: The Art of Oncology episode "A Fight Bigger Than Myeloma” with host Dr. Mikkael Sekeres & Dr. Adeel Khan who uses pt's multiple myeloma story to highlight civil liberties progress & the work still ahead.

🎧: brnw.ch/21wWO0S
#mmsm

We're thrilled to be here on BlueSky to bring you the latest practice-changing oncology research from all six JCO Journals! Follow-us for great content from #JCO, #JCOOP, #JCOGO, #JCOPO, #JCOCCI, & #JCOOA.

ASCO Publications

🌟🟠 HER2 in mCRC
New pooled analysis in JCO
(8 RCTs, n=1,604)🌟

✅ HER2+ = worse PFS & OS
❌ Not predictive for Bev vs anti-EGFR
➡️ Prognostic, not predictive

#GIOnc #ColorectalCancer #mCRC #HER2 #Oncology #JCO #Medicalwatch

ascopubs.org/doi/10.1200/...

Joint commission visit DONE!! My perfect streak of never directly interacting with a surveyor ended after 24 yrs, but just some facility info not about patient care/safety. #JCAHO #JCo #nurselife
#iykyk

"Ordinarily, if you get up at 7, you get something done." #JoyceCarolOates #JCO

Uttarakhand cloudburst: 50 civilians, JCO, 8 jawans still missing in Dharali New Delhi, Aug 7 ( IANS) At least 50 civilians, eight jawans and a Junior Commissioned Officer (JCO) are still missing after a cloudburst triggered flash flood and landslides in Dharali in Uttarakhand's Uttarkashi district early this week. After the cloudburst in the Dharali region near Harsil on August 5, the area remains largely inaccessible, with key road links at Bartwari, Linchigad, Gangrani, Harsil, and Dharali severely damaged.

Uttarakhand cloudburst: 50 civilians, JCO, 8 jawans still missing in Dharali #Uttarakhand #JCO #Dharali #socialnewsxyz

Our early-phase trial of DEP-SN38, a poly-lysine dendrimer–conjugated SN38 platform, is now published @ascocancer.bsky.social #JCO @oncocook.bsky.social
💡As TOP1I ADC programs rise, there's growing interest in better payload delivery—and not just through antibodies.
Can dendrimers assist? ⬇️🧵

‼️ #ASCO25 #JCO simultaneous publication by Jagannath et al: 

Long-Term (≥5 year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory #MultipleMyeloma. Read the full article: brnw.ch...

The phase III MITO-23 trial compared trabectedin monotherapy to physician’s choice chemo in 244 patients with BRCA-mutated or BRCAness recurrent ovarian cancer.

@ascocancer.bsky.social #JCO #ASCO

#Onco404 #Cancer #Kanser #OvarianCancer #MedSky #OncSky #BRCA #BRCAness #Trabectedin #ClinicalTrials

The final analysis of the INTRIGUE phase III trial reveals ripretinib and sunitinib show comparable overall survival in advanced GIST patients post-imatinib.

@ascocancer.bsky.social #JCO #ASCO

#Onco404 #Cancer #Kanser #GIST #Ripretinib #Sunitinib #ClinicalTrials #MedSky #OncSky

This presentation at @wasm.io was a blast to do (if my voice was missing), but the work that @tschneidereit.bsky.social of @fermyon.com did here to wire up a general solution for interpreted language debugging in @vscode.dev using #starlingmonkey and #jco as the example is amazing.

Implement wasi preview3 nodejs shim by andreiltd · Pull Request #653 · bytecodealliance/jco This pull request introduces the new preview3-shim package, which provides WASI preview3 implementations for Node.js. These implementations align with the WIT file definitions from the WASI preview...

OMFG I can't wait. @tandrz.bsky.social has submitted a PR for the #webassembly #wasi v0.3.0 (Preview 3) nodejs compat on #jco! github.com/bytecodealli....

This movement is fantastic.

Ramy Sedhom: JCO Piece on Hope and Communication in Oncology - OncoDaily Ramy Sedhom: JCO Piece on Hope and Communication in Oncology / Benjamin W. Corn, cancer, David B. Feldman, fight against cancer, Global fight against cancer,

Ramy Sedhom: JCO Piece on Hope and Communication in Oncology
@rsedhom.bsky.social

oncodaily.com/science/ramy...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #JCO

Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia PURPOSEThis randomized phase-II trial (ClinicalTrials.gov identifier: NCT02767557) compared efficacy of gemcitabine/nab-paclitaxel (Gem/Nab) with or without the anti–interleukin-6 (IL-6) receptor anti...

New JCO study from Teresa Zimmers, PhD: Tocilizumab + gem/nab-paclitaxel didn't change median OS, but improved 18-mo survival and reduced cachexia in adv pancreatic cancer. IL-6 blockade may support precision anticachexia strategies.

To read:
bit.ly/tz51525

#PancreasResearch #Cachexia #JCO #BCCPC

The phase II LUMINOSITY trial evaluated telisotuzumab vedotin (Teliso-V) in advanced c-Met protein-overexpressing, nonsquamous EGFR-wildtype NSCLC.

@ascocancer.bsky.social #JCO

#Onco404 #Cancer #Kanser #LungCancer #AkciğerKanseri #MedSky #OncSky #PrecisionMedicine #ClinicalTrials #cMET #ADC